Aurora Cannabis Sales Drop 10%, But Beats Estimates

After the market closed on Thursday, Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) delivered results for the second quarter fiscal 2022 ending December 31, 2021. Aurora reported that second quarter total cannabis net revenue was $60.6 million, up 1% sequentially but down from last year’s $67 million. This beat the analysts estimates for revenue which was just $46 million according to Yahoo Finance. As a result, the stock was trading almost 2% higher to lately sell at $4.70.

The company also delivered a net loss of $75 million for the quarter, which was an improvement over last year’s net loss of $300 million.

The average net selling price per gram of dried cannabis excluding the effect of bulk wholesale of excess mid-potency cannabis flower during the quarter, declined 10% to $4.20 from $4.67 in the first quarterQ1 2022 reflecting continued downward pressures on pricing due to competition.

“During the second quarter, we improved our Adjusted EBITDA by $2.5 million over Q1, moving us closer to our profitability goal. Our focus remains on further cost reductions, and we are pleased to announce today that we expect to reach the high end of the $60 to $80 million range. Our balance sheet remains among the strongest in the industry, with approximately $445 million in cash as of yesterday. This gives us significant working capital to support organic growth and positions us to pursue strategic M&A opportunities,” stated Miguel Martin, Chief Executive Officer of Aurora.

Cantor Fitzgerald analyst Pablo Zuanic reiterated a neutral rating on the company but dropped his 12-month price target to C$7.60 from C$10.75 due to reduced sales estimates. Zuanic said the company remains a long-term turnaround story. “We realize pressures in the domestic recreational unit, in part, offset progress in other areas, so trend-wise we are constructive, but do not have enough fodder to upgrade the stock.”

“Q2 total cannabis net revenue held steady sequentially, driven by our industry leading, high margin global medical cannabis business. New international markets are rapidly opening, and with the unique ability to navigate complex regulatory environments, we see a significant revenue opportunity of which we are at the forefront. While the Canadian adult-use market continues to face challenges, we are focused on introducing a new range of products set to launch this spring,” he concluded.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.


Leave a Reply

Your email address will not be published. Required fields are marked *

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 35 mins

Researchers Seek to Remove ‘Trip’ as Popularity of Psychedelic Treatments Grows

@GreenMarketRpt – 3 hours

The Weekly Stash Video September 30, 2022

@GreenMarketRpt – 3 hours

Florida Drops Criminal Charges Against Former Ascend Wellness Chief

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.